Literature DB >> 7555035

Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man.

M Verho1, C Luck, W J Stelter, B Rangoonwala, N Bender.   

Abstract

In order to evaluate the pharmacokinetics and excretion of ramipril in man, 8 cholecystectomy patients aged between 53 and 68 years received 5 mg ramipril orally as a single dose. All patients had a T-drain inserted to permit bile collection; all gave their informed consent to participate in the trial. Serum samples were collected half-hourly until 2 hours, then hourly until 6 hours, then at 8, 10, 24 and 25 hours after intake. Urine was collected in 2-hour fractions until 8 hours, followed by a 4- and a 12-hour fraction. Bile was collected hourly until 6 hours, followed by a 6- and a 12-hour collecting fraction. Concentrations of ramipril and ramiprilat in serum, and determinations in urine and bile of ramipril, ramiprilat, ramipril glucuronide, ramiprilat glucuronide, diketopiperazine and diketopiperazine acid were made; total amounts excreted were calculated. Peak concentrations of ramiprilat in plasma (8.7 +/- 1.6 ng/ml) were reached after about 8 hours. AUC0-8 and AUC0-24-values were 36.5 and 111.9 ng.h/ml, respectively. Ramiprilat Cmax-concentrations were about 300-fold higher in bile than in plasma, the corresponding difference for ramipril between bile and plasma was about 4-fold. The main fractions excreted in the urine were diketopiperazine acid and ramiprilat amounting to 13.2 +/- 5.6 and 4.4 +/- 2.4%, respectively, of the dose administered. Only a very small fraction of the dose was excreted with urine as unchanged ramipril, on average 0.9 +/- 1.0%. The main fractions excreted in the bile were diketopiperazine acid, ramiprilat glucuronide and diketopiperazine, 9.0 +/- 5.3, 3.4 +/- 4.2 and 2.0 +/- 1.2% in 24 hours, respectively, of the dose administered. Only a negligible fraction of the dose (average 0.1 +/- 0.1%) was excreted with bile as unchanged ramipril. In conclusion, there is strong evidence that circulating ramipril and ramiprilat are eliminated by both the liver and the kidneys. For the patients studied it can be estimated from late collection periods that some 2/3 of circulating ramipril and ramiprilat are eliminated by the kidneys and 1/3 eliminated by the liver.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7555035     DOI: 10.1185/03007999509111551

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

Review 1.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

2.  Predicted environmental concentration and fate of the top 10 most dispensed Australian prescription pharmaceuticals.

Authors:  Timothy T X Ong; Ewan W Blanch; Oliver A H Jones
Journal:  Environ Sci Pollut Res Int       Date:  2018-02-04       Impact factor: 4.223

3.  Human Health Relevance of Pharmaceutically Active Compounds in Drinking Water.

Authors:  Usman Khan; Jim Nicell
Journal:  AAPS J       Date:  2015-03-05       Impact factor: 4.009

Review 4.  Methods to evaluate biliary excretion of drugs in humans: an updated review.

Authors:  Giulia Ghibellini; Elaine M Leslie; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

Review 5.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

6.  Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.

Authors:  David G Levitt; Rik C Schoemaker
Journal:  BMC Clin Pharmacol       Date:  2006-01-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.